Re-evaluating oral anticoagulant therapies for stroke prevention in atrial fibrillation (SPAF)
Tuesday 4th October, 10:45 - 12:15 in the Arden Room, Hilton Birmingham Metropole
For over 50 years warfarin has been the only oral anticoagulant available for stroke prevention in atrial fibrillation, now we have a choice of agents in our armamentarium.
- What will be the clinical impact of dabigatran?
- Which patients are we likely to consider for its initial use?
- What will be the practicalities and hurdles?
- What benefits might dabigatran offer patients, healthcare professionals and the health economy?
Join us in the Den as our two brave 'entrepreneurs' pitch Pradaxa®▼ (dabigatran etexilate) for SPAF in different patient cohorts.
Having made their pitch to our Dragons, it's over to you to decide whether you are IN or OUT!
Chair:
Sue Lawley
Broadcaster and Journalist
Broadcaster and Journalist
Dragons:
Professor John Camm
BHF Professor of Clinical Cardiology, London
Dr Damian Jenkinson
Consultant Physician, Bournemouth
BHF Professor of Clinical Cardiology, London
Dr Damian Jenkinson
Consultant Physician, Bournemouth
Entrepreneurs:
Dr Sarah Jarvis
General Practitioner and Medical Broadcaster, London
Dr Ian Menown
Consultant Cardiologist, Belfast
General Practitioner and Medical Broadcaster, London
Dr Ian Menown
Consultant Cardiologist, Belfast
